Semin intervent Radiol 2013; 30(02): 093-098
DOI: 10.1055/s-0033-1342949
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Epidemiology of Lung Cancer

Carole A. Ridge
1   Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, New York
,
Aoife M. McErlean
2   Department of Radiology, Beaumont Hospital, Dublin, Ireland
,
Michelle S. Ginsberg
1   Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, New York
› Author Affiliations
Further Information

Publication History

Publication Date:
28 May 2013 (online)

Abstract

Incidence and mortality attributed to lung cancer has risen steadily since the 1930s. Efforts to improve outcomes have not only led to a greater understanding of the etiology of lung cancer, but also the histologic and molecular characteristics of individual lung tumors. This article describes this evolution by discussing the extent of the current lung cancer epidemic including contemporary incidence and mortality trends, the risk factors for development of lung cancer, and details of promising molecular targets for treatment.

 
  • References

  • 1 American Cancer Society. Cancer Facts and Figures 2012. Atlanta, GA: 2012. Available at: http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-031941.pdf
  • 2 Adler I. Primary malignant growths of the lungs and bronchi. New York, NY: Longmans, Green; 1912
  • 3 Harting FH, Hesse W. Der Lungenkrebs, die Bergenkrankheit in den Schneeberger gruben. Vierteljahresschr Gerichtl Med 1879; 30: 296-309
  • 4 Rubin SA. Lung cancer: past, present, and future. J Thorac Imaging 1991; 7 (1) 1-8
  • 5 Arnstein A. Uber den sogenannten “Schneeberger Lungenkrebs.”. Wien Klin Wchnshcr. 1913; 26: 748-752
  • 6 Ochsner A, DeBakey M. Symposium on cancer: Primary pulmonary malignancy. Treatment by total pneumonectomy, analysis of 70 collected cases and presentation of 7 personal cases. Surg Gynecol Obstet 1939; 68: 435-451
  • 7 Doll R, Hill AB. Smoking and carcinoma of the lung; preliminary report. BMJ 1950; 2 (4682) 739-748
  • 8 Royal College of Physicians. Smoking and health. A report on smoking in relation to lung cancer and other diseases. London, United Kingdom: Royal College of Physicians; 1962
  • 9 Terry LL. Smoking and Health: Report of the Advisory Committee to the Surgeon General of the Public Health Service. In: U-23 U.S. Department of Health, Education, and Welfare. Public Health Service; Publication No. 1103. Washington, DC: U.S. Department of Health, Education, and Welfare; 1964
  • 10 Department of Health and Human Services (DHHS). The Health Consequences of Smoking. Cancer: a Report of the Surgeon General. Rockville, MD: DHHS; 1982
  • 11 Fielding JE. Smoking: health effects and control (1). N Engl J Med 1985; 313 (8) 491-498
  • 12 Ferlay J, Shin HR, Bray F , et al. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. Lyon, France: International Agency for Research on Cancer; 2010. . Available from: http://globocan.iarc.fr
  • 13 Howlader N, Noone AM, Krapcho M , et al , eds. SEER Cancer Statistics Review, 1975–2009 (Vintage 2009 Populations), National Cancer Institute. Bethesda, MD. Available at: http://seer.cancer.gov/csr/1975_2009_pops09/ , based on November 2011 SEER data submission, posted to the SEER Web site, April 2012
  • 14 National Cancer Institute. SEER Cancer Statistics Review 1975–2008. Lifetime Risk (Percent) of Being Diagnosed with Cancer by Site and Race/Ethnicity: Males, 17 SEER Areas, 2006–2008 (Table 1.15) and Females, 17 SEER Areas, 2006–2008 (Table 1.16). 2011. Available at: http://seer.cancer.gov/csr/1975_2008/results_merged/topic_lifetime_risk_diagnosis.pdf . Accessed October 15, 2012
  • 15 Youlden DR, Cramb SM, Baade PD. The International Epidemiology of Lung Cancer: geographical distribution and secular trends. J Thorac Oncol 2008; 3 (8) 819-831
  • 16 Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006; 24 (14) 2137-2150
  • 17 Janssen-Heijnen ML, Coebergh JW. Trends in incidence and prognosis of the histological subtypes of lung cancer in North America, Australia, New Zealand and Europe. Lung Cancer 2001; 31 (2–3) 123-137
  • 18 Devesa SS, Bray F, Vizcaino AP, Parkin DM. International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising. Int J Cancer 2005; 117 (2) 294-299
  • 19 Chen K, Wang PP, Sun B , et al. Twenty-year secular changes in sex specific lung cancer incidence rates in an urban Chinese population. Lung Cancer 2006; 51 (1) 13-19
  • 20 Bosetti C, Malvezzi M, Chatenoud L, Negri E, Levi F, La Vecchia C. Trends in cancer mortality in the Americas, 1970–2000. Ann Oncol 2005; 16 (3) 489-511
  • 21 Lam WK, White NW, Chan-Yeung MM. Lung cancer epidemiology and risk factors in Asia and Africa. Int J Tuberc Lung Dis 2004; 8 (9) 1045-1057
  • 22 Jemal A, Thun MJ, Ries LAG , et al. Annual report to the nation on the status of cancer, 1975–2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst 2008; 100 (23) 1672-1694
  • 23 Kligerman S, White C. Epidemiology of lung cancer in women: risk factors, survival, and screening. AJR Am J Roentgenol 2011; 196 (2) 287-295
  • 24 Women and Smoking. A Report of the Surgeon General. Washington, DC: United States Department of Health and Human Services, Public Health Service, Office of the Surgeon General; 2001
  • 25 Risch HA, Howe GR, Jain M, Burch JD, Holowaty EJ, Miller AB. Are female smokers at higher risk for lung cancer than male smokers? A case-control analysis by histologic type. Am J Epidemiol 1993; 138 (5) 281-293
  • 26 Zang EA, Wynder EL. Differences in lung cancer risk between men and women: examination of the evidence. J Natl Cancer Inst 1996; 88 (3–4) 183-192
  • 27 Henschke CI, Yip R, Miettinen OS. International Early Lung Cancer Action Program Investigators. Women's susceptibility to tobacco carcinogens and survival after diagnosis of lung cancer. JAMA 2006; 296 (2) 180-184
  • 28 Kure EH, Ryberg D, Hewer A , et al. p53 mutations in lung tumours: relationship to gender and lung DNA adduct levels. Carcinogenesis 1996; 17 (10) 2201-2205
  • 29 Patel JD, Bach PB, Kris MG. Lung cancer in US women: a contemporary epidemic. JAMA 2004; 291 (14) 1763-1768
  • 30 Travis WD, Brambilla E, Noguchi M , et al; American Thoracic Society. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary. Proc Am Thorac Soc 2011; 8 (5) 381-385
  • 31 Patel JD. Lung cancer in women. J Clin Oncol 2005; 23 (14) 3212-3218
  • 32 Surgeon General. Reducing the Health Consequences of Smoking: 25 Years of Progress. Washington, DC: U.S. Government Printing Office; 1989
  • 33 Shopland DR. Tobacco use and its contribution to early cancer mortality with a special emphasis on cigarette smoking. Environ Health Perspect 1995; 103 (Suppl. 08) 131-142
  • 34 Pfeifer GP, Denissenko MF, Olivier M, Tretyakova N, Hecht SS, Hainaut P. Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene 2002; 21 (48) 7435-7451
  • 35 Vineis P, Alavanja M, Buffler P , et al. Tobacco and cancer: recent epidemiological evidence. J Natl Cancer Inst 2004; 96 (2) 99-106
  • 36 Stellman SD, Muscat JE, Thompson S, Hoffmann D, Wynder EL. Risk of squamous cell carcinoma and adenocarcinoma of the lung in relation to lifetime filter cigarette smoking. Cancer 1997; 80 (3) 382-388
  • 37 Devesa SS, Shaw GL, Blot WJ. Changing pattern of lung cancer incidence by histological type. Cancer Epidemiol Biomarkers Prev 1997; 1: 29-34
  • 38 Patel AR, Obrams GI. Adenocarcinoma of the lung: meeting report. Cancer Epidemiol Biomarkers Prev 1997; 4: 175-180
  • 39 Harris JE, Thun MJ, Mondul AM , et al. Cigarette tar yields in relation to mortality from lung cancer in the cancer prevention study II prospective cohort, 1982–8. BMJ 2004; 328: 1-8
  • 40 Benowitz N. Compensatory smoking of low-yield cigarettes. In: Shopland DR, Burns DM, Benowitz NI, Amacher RH, , eds. Risks Associated with Smoking Cigarettes with Low Machine-Measured Yields of Tar and Nicotine [NCI Smoking and Tobacco Control Monograph No. 13]. Bethesda, MD: U.S. National Institutes of Health, National Cancer Institute; 2001: 39-64
  • 41 Pawel DJ, Puskin JS. The U.S. Environmental Protection Agency's assessment of risks from indoor radon. Health Phys 2004; 87 (1) 68-74
  • 42 Pershagen G, Akerblom G, Axelson O , et al. Residential radon exposure and lung cancer in Sweden. N Engl J Med 1994; 330 (3) 159-164
  • 43 Schoenberg JB, Klotz JB, Wilcox HB , et al. Case-control study of residential radon and lung cancer among New Jersey women. Cancer Res 1990; 50 (20) 6520-6524
  • 44 Barros-Dios JM, Barreiro MA, Ruano-Ravina A, Figueiras A. Exposure to residential radon and lung cancer in Spain: a population-based case-control study. Am J Epidemiol 2002; 156 (6) 548-555
  • 45 National Research Council. Environmental Tobacco Smoke: Measuring Exposures and Assessing Health Effects. Washington, DC: National Academy Press; 1986
  • 46 US Department of Health and Human Services (DHHS). The Health Consequences of Involuntary Smoking. A Report of the Surgeon General [Publication No. (PHS) 87–8398]. Washington, DC: DHHS; 1986
  • 47 Hecht SS, Carmella SG, Murphy SE, Akerkar S, Brunnemann KD, Hoffmann D. A tobacco-specific lung carcinogen in the urine of men exposed to cigarette smoke. N Engl J Med 1993; 329 (21) 1543-1546
  • 48 Hackshaw AK, Law MR, Wald NJ. The accumulated evidence on lung cancer and environmental tobacco smoke. BMJ 1997; 315 (7114) 980-988
  • 49 Doll R, Peto R. The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J Natl Cancer Inst 1981; 66 (6) 1191-1308
  • 50 Neuberger JS, Field RW. Occupation and lung cancer in nonsmokers. Rev Environ Health 2003; 18 (4) 251-267
  • 51 Johnson BE. Second lung cancers in patients after treatment for an initial lung cancer. J Natl Cancer Inst 1998; 90 (18) 1335-1345
  • 52 Engels EA, Biggar RJ, Hall HI , et al. Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer 2008; 123 (1) 187-194
  • 53 Chaturvedi AK, Pfeiffer RM, Chang L, Goedert JJ, Biggar RJ, Engels EA. Elevated risk of lung cancer among people with AIDS. AIDS 2007; 21 (2) 207-213
  • 54 D'Jaen GA, Pantanowitz L, Bower M , et al. Human immunodeficiency virus-associated primary lung cancer in the era of highly active antiretroviral therapy: a multi-institutional collaboration. Clin Lung Cancer 2010; 11 (6) 396-404
  • 55 Ford MB, Sigurdson AJ, Petrulis ES , et al. Effects of smoking and radiotherapy on lung carcinoma in breast carcinoma survivors. Cancer 2003; 98 (7) 1457-1464
  • 56 Deutsch M, Land SR, Begovic M, Wieand HS, Wolmark N, Fisher B. The incidence of lung carcinoma after surgery for breast carcinoma with and without postoperative radiotherapy. Results of National Surgical Adjuvant Breast and Bowel Project (NSABP) clinical trials B-04 and B-06. Cancer 2003; 98 (7) 1362-1368
  • 57 Eaton DK, Kann L, Kinchen S , et al; Centers for Disease Control and Prevention (CDC). Youth risk behavior surveillance—United States, 2011. MMWR Surveill Summ 2012; 61 (4) 1-162
  • 58 Centers for Disease Control and Prevention (CDC). Vital signs: current cigarette smoking among adults aged ≥18 years—United States, 2005–2010. MMWR Morb Mortal Wkly Rep 2011; 60 (35) 1207-1212
  • 59 World Health Organization. Global Status Report on Noncommunicable Diseases 2010. Geneva, Switzerland: World Health Organization; 2011
  • 60 Shigematsu H, Gazdar AF. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer 2006; 118 (2) 257-262
  • 61 Pao W, Miller V, Zakowski M , et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004; 101 (36) 13306-13311
  • 62 Costa DB, Kobayashi S, Tenen DG, Huberman MS. Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers. Lung Cancer 2007; 58 (1) 95-103
  • 63 Mok TS, Wu YL, Thongprasert S , et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361 (10) 947-957
  • 64 Rosell R, Carcereny E, Gervais R , et al; Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012; 13 (3) 239-246
  • 65 Riely GJ, Marks J, Pao W. KRAS mutations in non-small cell lung cancer. Proc Am Thorac Soc 2009; 6 (2) 201-205
  • 66 Buttitta F, Barassi F, Fresu G , et al. Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: mutations are mainly present in adenocarcinomas with bronchioloalveolar features. Int J Cancer 2006; 119 (11) 2586-2591
  • 67 Suzuki M, Shigematsu H, Iizasa T , et al. Exclusive mutation in epidermal growth factor receptor gene, HER-2, and KRAS, and synchronous methylation of nonsmall cell lung cancer. Cancer 2006; 106 (10) 2200-2207
  • 68 Eberhard DA, Johnson BE, Amler LC , et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005; 23 (25) 5900-5909
  • 69 Kwak EL, Bang YJ, Camidge DR , et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010; 363 (18) 1693-1703
  • 70 Rekhtman N, Paik PK, Arcila ME , et al. Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations. Clin Cancer Res 2012; 18 (4) 1167-1176
  • 71 Hammerman PS, Hayes DN, Wilkerson MD , et al; Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012; 489 (7417) 519-525